Advances in the development of gene and cell therapies have progressed very fast during the last 10 years. Novel advanced therapies of complex diseases currently constitute additional aims of the Hematopoietic Innovative Therapies Division. In this new Unit, innovative therapeutic programs for inflammatory and immune diseases are being developed based on the use of genetically modified mesenchymal stromal cells and regulatory T cells. Additionally developments in the field of gene therapy have allowed us to start new gene therapy programs for platelet disorders and also for specific haematological and solid tumours using CAR-T and CAR-NK cells. Finally, novel gene therapy approaches based on the development of nanotechnology strategies are being developed as a horizontal research line coordinated with the rest of the programs of the Biomedical Innovation Unit.